Navigation Links
Fragile X and Down syndromes share signalling pathway for intellectual disability
Date:8/3/2012

HEIDELBERG, 3 August 2012 Intellectual disability due to Fragile X and Down syndromes involves similar molecular pathways report researchers in The EMBO Journal. The two disorders share disturbances in the molecular events that regulate the way nerve cells develop dendritic spines, the small extensions found on the surface of nerve cells that are crucial for communication in the brain.

"We have shown for the first time that some of the proteins altered in Fragile X and Down syndromes are common molecular triggers of intellectual disability in both disorders," said Kyung-Tai Min, one of the lead authors of the study and a professor at Indiana University and the Ulsan National Institute of Science and Technology in Korea. "Specifically, two proteins interact with each other in a way that limits the formation of spines or protrusions on the surface of dendrites." He added: "These outgrowths of the cell are essential for the formation of new contacts with other nerve cells and for the successful transmission of nerve signals. When the spines are impaired, information transfer is impeded and mental retardation takes hold."

Intellectual disability is a developmental brain disorder that leads to impaired cognitive performance and mental retardation. Two of the most prevalent genetic causes of intellectual disability in humans are Fragile X and Down syndromes. Fragile X syndrome arises from a single gene mutation that prevents the synthesis of a protein required for neural development (Fragile X mental retardation protein). The presence of all or a part of a third copy of chromosome 21 in cells causes Down syndrome. Although both syndromes arise due to these fundamental genetic differences, the researchers identified a shared molecular pathway in mice that leads to intellectual disability for both disorders.

The mice that were used in the experiments are model systems for the study of Fragile X syndrome and Down syndrome. Down syndrome mice have difficulties with memory and brain function, and the formation of the heart is often compromised, symptoms that are also observed in humans with Down syndrome. Both model systems are very useful to scientists looking to dissect the molecular events that occur as the disorders take hold.

The scientists revealed that the Down syndrome critical region 1 protein (DSCR1) interacts with Fragile X mental retardation protein (FMRP) to regulate dendritic spine formation and local protein synthesis. By using specific antibodies that bind to the proteins as well as fluorescent labeling techniques they showed that DSCR1 specifically interacts with the phosphorylated form of FMRP. The overlapping molecular pathways of intellectual disability in both genetic disorders suggest that a common therapeutic approach might be feasible for both syndromes.

Min remarked: "We believe these experiments provide an important step forward in understanding the multiple roles of DSCR1 in neurons and in identifying a molecular interaction that is closely linked to intellectual disability for both syndromes."

DSCR1 interacts with FMRP and is required for spine morphogenesis and local protein synthesis


'/>"/>
Contact: Barry Whyte
barry.whyte@embo.org
49-622-188-91108
European Molecular Biology Organization
Source:Eurekalert  

Related biology news :

1. Stem cell research paves way for progress on dealing with Fragile X retardation
2. Stanford scientists document fragile land-sea ecological chain
3. A new pipewort species from a unique, but fragile habitat in India
4. Myelodysplastic syndromes (MDS) linked to abnormal stem cells
5. F1000 Research partners with figshare to provide smart ways of accessing data
6. Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
7. Gut microbes battle a common set of viruses shared by global populations
8. UCSB researchers to examine the effects of year-old NOAA West Coast Catch Shares program
9. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
10. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
11. A new candidate pathway for treating visceral obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fragile X and Down syndromes share signalling pathway for intellectual disability
(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security ... solutions for the Biometric Exit Program. The Request for ... (CBP), explains that CBP intends to add biometrics to ... United States , in order to deter visa ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... ... December 06, 2016 , ... ... platforms, announced today that the company has engaged in a collaborative research partnership ... (MRDA) with the CSU Office of the Vice President for Research. This agreement ...
(Date:12/6/2016)... PARK, Calif. , Dec. 6, 2016 /PRNewswire/ ... up to $150 million from the National Institutes ... Diseases and the Division of AIDS (NIAID-DAIDS) to ... and other non-vaccine pre-exposure (PreP) agents. Under the ... of preclinical product development services for candidate HIV-prevention ...
(Date:12/5/2016)... ... 2016 , ... This composition patent, U.S. Patent No. 9,499,637, ... composition claims are not limited to any particular process to make or use ... fibers, graphene, and other materials. A continuation application, U.S. Patent App. No. ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
Breaking Biology Technology: